


PRODUCT INFORMATION



Abiraterone Acetate-d₄

Item No. 22096

Formal Name: (3β)-17-(3-pyridinyl-d₄)-androsta-5,16-dien-3-ol, acetate ester
Synonym: CB-7630-d₄
MF: C₂₆H₂₉D₄NO₂
FW: 395.6
Chemical Purity: ≥98% (Abiraterone Acetate)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₄); ≤1% d₀
Supplied as: A solid
Storage: 4°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Abiraterone acetate-d₄ is intended for use as an internal standard for the quantification of abiraterone acetate (Item No. 15148) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Abiraterone acetate-d₄ is supplied as a solid. A stock solution may be made by dissolving the solid in the solvent of choice, which should be purged with an inert gas. Abiraterone acetate-d₄ is soluble in the organic solvent methanol.

Description

Abiraterone acetate is an inhibitor of the cytochrome P450 (CYP) isoform CYP17A1 (IC₅₀s = 17 and 18 nM for inhibition of C_{17,20}-lyase and 17α-hydroxylase activities, respectively).¹ It is also a prodrug form of abiraterone (Item No. 9002768).² Abiraterone acetate reduces plasma testosterone levels, increases plasma luteinizing hormone levels, and reduces ventral prostate, seminal vesicle, testis, and kidney weight in mice when administered at doses of 0.1 and 0.5 mmol/kg per day. It also reduces severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in the culture supernatant of infected Vero E6 cells (EC₉₀ = 8.4 μM) and is active in a plaque reduction assay (EC₅₀ = 1.94 μM).³ Formulations containing abiraterone acetate have been used in combination therapy for the treatment of metastatic castration-resistant prostate cancer.

References

1. Potter, G.A., Barrie, S.E., Jarman, M., *et al.* Novel steroidal inhibitors of human cytochrome P450_{17α} (17α-hydroxylase-C_{17,20}-lyase): Potential agents for the treatment of prostatic cancer. *J. Med. Chem.* **38(13)**, 2463-2471 (1995).
2. Barrie, S.E., Potter, G.A., Goddard, P.M., *et al.* Pharmacology of novel steroidal inhibitors of cytochrome P450_{17α} (17α-hydroxylase/C17-20 lyase). *J. Steroid Biochem. Mol. Biol.* **50(5-6)**, 267-273 (1994).
3. Yuan, S., Chan, J.F.W., Chik, K.K.H., *et al.* Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. *Pharmacol. Res.* **159(104960)**, (2020).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/30/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM